Objective. This study was performed to assess the cost-effectiveness of cyclooxygenase-2 (COX2)-selective inhibitor, non-selective non-steroidal anti-inflammatory drugs (NSAIDs), and non-selective NSAID with proton pump inhibitors (PPIs) while considering upper and lower gastrointestinal (GI) safety in patients with rheumatoid arthritis (RA). Methods. A Markov model was used to estimate the costs and effectiveness. Estimates of therapeutic efficacy and upper/lower GI safety were based on results from large randomized controlled trials. The main outcome measure was cost effectiveness, based on the quality-adjusted life years (QALYs) gained. Safety parameters included clinical upper GI symptoms, uncomplicated ulcer, upper GI bleeding, upper GI perforation, clinical lower GI symptoms, lower GI bleeding, and lower GI perforation. Cost data were obtained from patients treated in a tertiary referral center in Korea. Results. The expected three year cost was 3,052,800 Korean won (KRW) for COX2-selective inhibitor, 3,170,800 KRW for nonselective NSAID, and 3,325,900 KRW for non-selective NSAID with PPI. QALYs were 2.87446, 2.85320, and 2.85815, respectively. The total cost for COX2-selective inhibitor use was lower than non-selective NSAID, but QALY was higher, indicating that the incremental cost effectiveness ratio of COX2-selective inhibitor is superior. Conclusion. COX2-selective inhibitor has reasonable cost-effectiveness adjusted for upper and lower GI toxicity for patients with RA in Korea. (J Rheum Dis 2017;24:27-34)
INTRODUCTION
Non-steroidal anti-inflammatory drugs (NSAIDs) are one of the most frequently used drugs for the treatment of rheumatoid arthritis (RA) [1, 2] . NSAIDs can cause several adverse reactions, such as gastrointestinal (GI) complications, azotemia, platelet dysfunction, allergic rhinitis, aggravation of asthma, skin rash, liver toxicity and bone marrow suppression [3, 4] . Especially, NSAID-related GI complications are one of the most frequently encountered problems in clinical settings. Ten to sixty percent of patients experience dyspepsia while taking NSAIDs, and 4% to 40% of patients suffer from ulcers in the upper GI tract. Five to fifteen percent of patients with RA may discontinue NSAIDs due to dyspepsia within 6 months, and the mortality of NSAID-induced bleeding reaches up to 5% to 10% [5, 6] .
To reduce GI complications caused by NSAID uses, co-administration of proton pump inhibitor (PPI) with conventional NSAIDs, and replacement of conventional NSAIDs with selective cyclooxygenase-2 (COX-2) inhibitor, have been widely used. There are several reports showing that PPIs can prevent the development of gastric or duodenal ulcers through the inhibition of gastric acid secretion and co-administration of PPI with NSAIDs can reduce the risk of upper GI toxicity [7] [8] [9] [10] . Another way to prevent GI complications for patients taking NSAIDs for treatment of their arthritis is to replace non-selective NSAIDs with selective COX-2 inhibitors. The COX enzyme family consists of COX-1 and COX-2 isoenzymes. COX-1 is constitutionally expressed and controls normal physiologic reactions, such as maintenance of gastric mucosal integrity. COX-2 is expressed only after inflammatory reaction and regulates pain and inflammation. Previous studies suggest that GI adverse events of conventional NSAIDs are mediated through the inhibition of COX-1 enzyme, and selective COX-2 inhibitors could decrease the risk of GI complications of NSAID [11] [12] [13] .
In the latest decade, there have been great developments in the treatment of RA, and various kinds of drugs have been used for RA treatment. However, NSAIDs are still being one of the most frequently prescribed agents for RA treatment in Korea [14] , thus selecting more efficient and safer ways is as crucial as developing new agents for treatment of RA. Most of previous studies on safety of NSAIDs have focused upper GI toxicity caused by NSAIDs use, but recent reports have addressed that NSAIDs use is also strongly related to the development of lower GI complications and that selective COX-2 inhibitor can reduce the incidence of NSAID induced lower GI complications [15] [16] [17] [18] [19] [20] .
Despite the increased interest in lowering GI toxicity of NSAID, there have been no pharmacoeconomic studies specifically focused on lowering GI toxicity of NSAIDs. This study was performed to assess the cost-effectiveness of a selective COX-2 inhibitor, non-selective NSAID, and non-selective NSAID with PPI with regards to GI safety in patients with RA. In this study, cost-effectiveness of each treatment strategy was compared considering lower GI toxicity as well as upper GI toxicity.
MATERIALS AND METHODS

Subject drugs
Non-selective NSAIDs and a selective COX-2 inhibitor were used to compare the cost and efficacy. Naproxen and meloxicam were chosen among non-selective NSAIDs because they are primarily used for treatment of RA in daily clinical practice of our institute, and celecoxib was chosen as a selective COX-2 inhibitor because it is the only selective COX-2 inhibitor approved for RA treatment in Korea.
Evaluation framework
This study assumed that non-selective NSAIDs and COX2-selective inhibitor were equally effective for the control of RA in terms of anti-inflammatory and analgesic effects. Any GI toxicity such as peptic ulcers, ulcer bleeding, and gastric or duodenal perforation was treated through hospitalization or on an outpatient basis. The treatment protocol of GI toxicity was based on clinical experience and textbook based algorithms [21] . If patients complain of clinical symptom alone that could not be proven by endoscopy, patients continued the NSAID treatment with GI protective agents on an outpatient basis. If ulcers were detected by endoscopy, NSAID was discontinued and GI protective agents or PPI was used for 8 weeks or longer. If GI bleeding was observed in addition to ulcers, then NSAID use is stopped and patients are hospitalized for endoscopic hemostasis. GI protective agents or PPI should be maintained for 8 weeks. If there were perforation, NSAID was discontinued, and surgical treatment was considered depending on the severity. If there were any GI problems in patients who were treated with non-selective NSAID, NSAIDs were switched to a COX2-selective inhibitor (Figure 1 ). A Markov model with a 12-week transition cycle was used to estimate the cost and effectiveness of each treatment groups with a 3-year time horizon, and comparative parameters were separated into three groups: COX2-selective inhibitor group, non-selective NSAID group, and non-selective NSAID with PPI group [22] . Modeling was conducted using TreeAge Pro 2009 software (TreeAge Software, Inc., Williamstown, MA, USA).
Input parameters
Variables for transition probability were improvement in RA symptoms and development of GI toxicity. Estimates of therapeutic efficacy were based on data from the Celecoxib Long-Term Arthritis Safety Study (CLASS) clinical study [19] . CLASS study is the largest randomized controlled trial which compared GI toxicity of celecoxib with NSAID for osteoarthritis (OA) and RA patients. A total of 7,968 outpatients aged 18 years or older, diagnosed as having RA or OA evident for at least 3 months and were expected to require continuous treatment with an NSAID for the duration of the trial received at least 1 dose of medication. Of these, more than 20% of the patients were taking low-dose aspirin (≤325 mg/d). In CLASS study, efficacy of each drug strategy assessed by patient's global assessment of arthritis after 26 week use of COX2-selective inhibitor 200 mg twice a day (bid), diclofenac 75 mg bid, and ibuprofen 800 mg three times a day. Improvement in arthritis was observed in 1,512 of 3,987 patients of celecoxib group (38%) and in 1,441 of 3,981 patients (36%) of diclofenac and ibuprofen groups. There is no difference in drug efficacy between these two groups. Thus, we assumed the improvement rate of COX2-selective inhibitor as 38%, and the improvement rate of NSAID as 36%. We assumed that PPI did not influence symptom improvement effect of NSAID, and thus we assumed the improvement rate of NSAID plus PPI group to be the same as NSAID group (36%) ( Table 1) .
Safety parameters included clinical upper GI symptoms such as reflux or dyspepsia, uncomplicated ulcer, upper GI bleeding, and upper GI perforation. Clinical lower GI symptoms such as diverticulitis or diarrhea, lower GI bleeding, and lower GI perforation were included. The complication probabilities of non-selective NSAID group and COX2-selective inhibitor group were cited from CLASS study after time-frame adjustment. Since there is no study with exactly matching complication probability of NSAID plus PPI group, and we substituted the same data with COX2-selective inhibitor group by author's best estimate. GI toxicity of NSAID with PPI is known to be equal or higher than COX2-selective inhibitor treatment [23] . Thus, we conservatively assumed that the GI toxicity of the two groups were equal. The prevention effect of lower GI toxicity of PPIs has not been proved. Thus, the toxicity of NSAID with PPI might be regarded as the same as that of the NSAID alone strategy ( Table 1) . The variables for effectiveness were utility of health states presented as quality of life (QOL) scores. The QOL scores of each health status were based on data from searched literature [22] . A utility of 0 for death and a utility of 1 for health states of complete recovery from RA were assumed. A utility of 0.688 for a patient with RA, 0.504 for health states of clinical upper GI events, 0.38 for uncomplicated upper GI ulcer, 0.312 for upper GI bleeding and 0 for upper GI perforation were quoted. QOL scores of lower GI complications were estimated to be equal to QOL scores of upper GI complications, because there was no prior cost-effectiveness study on lower GI complications ( Table 2) .
Data of medication and monitoring costs were derived from the database of the Health Insurance Review and Assessment Services of 2011∼2012. Cimetidine was chosen as primarily used GI protective agent and omeprazole as primarily used PPI. Monitoring cost was physician fee at the outpatient clinic, and distribution cost was the drug cost at the pharmacy. The cost for treating each GI event was determined by the treatment cost at our institute, a tertiary referral center in Seoul, Korea. Based on the treatment protocol of any GI toxicity such as peptic ulcers, ulcer bleeding, and gastric or duodenal perforation, the resource use was measured to estimate the cost of treating GI toxicity: hospitalization, medication, imaging tests, laboratory tests, procedures or surgery, and other medical treatment. The number of units consumed by each patient was multiplied by the cost per unit of each resource to estimate the direct costs for each patient. The cost data obtained in Korean won (KRW) are shown in Table 3 .
Incremental cost effectiveness ratio
In clinical practice, a realistic option may be to compare a new treatment strategy with the standard method. Thus, the difference in these costs would be of interest to the decision maker. The term 'incremental costs' is often used to refer to the difference between alternatives. The incremental cost effectiveness ratio (ICER) is the result of incremental cost of a new treatment to standard treatment divided by incremental effectiveness of new treatment to standard treatment [24] . The primary outcome measure was based on quality adjusted life years (QALY) gained, which is used in most cost effectiveness analysis studies [25, 26] . Utilities of health status were based on quality of life weight scores through a detailed review of the medical literatures.
RESULTS
Incremental cost effectiveness ratio (ICER)
Medication, monitoring costs, distribution cost and cost for treating each GI event were included in total cost. The expected 3 year total cost was 3,052,800 KRW for COX2-selective inhibitor treatment, 3,170,800 KRW for non-selective NSAID, and 3,325,900 KRW for non-selective NSAID with PPI. The direct medical cost of the COX2-selective inhibitor treatment group during routine management was also proven to be significantly lower. QALY for COX2-selective inhibitor treatment was 2.87446, for KRW: Korean won, QALY: quality-adjusted life year, ICER: incremental cost effectiveness ratio, NSAID: non-steroidal anti-inflammatory drug, PPI: proton-pump inhibitor. *The intervention costs less and is at least as effective as the comparator. † The intervention costs more and is no more effective than the comparator. nonselective NSAID 2.85320, and for non-selective NSAID with PPI 2.85533. The total cost for COX2-selective inhibitor was lower than non-selective NSAID but QALY was higher by 0.02126, and thus the ICER for COX2-selective inhibitor in comparison with non-selective NSAID showed dominance (Table 4 ). This result suggests that COX2-selective inhibitor can be considered to be cost effective.
Sensitivity analyses
Sensitivity analysis was performed for utility value. We substituted minimum zero to maximum 0.688 for health status of lower GI complications. After substitution, cost of COX2-selective inhibitor increased to 3,079,400 KRW, and QALYs rather increased or decreased (2.82900∼ 2.89100). The result also showed COX2-selective inhibitor strategy to be dominant ICER over non-selective NSAID or non-selective NSAID with PPI strategies.
DISCUSSION
In the present study, we performed pharmacoeconomic analysis on therapeutic efficacy and toxicities involving both upper and lower GI tracts of NSAIDs and found that the use of COX-2 selective inhibitor has a reasonable cost-effectiveness for patients with RA in Korea. Although the individual cost for COX-2 selective inhibitor is higher than non-selective NSAIDs and there is no evident difference in therapeutic efficacies between them, the use of COX-2 selective inhibitor appears to be economically attractive compared to non-selective NSAID alone or non-selective NSAID with PPI with regards to the devel-opment of upper and lower GI complications.
In the present study, several basic assumptions were made by authors' best estimate. First, we hypothesized that treatment with non-selective NSAID and PPI would show very similar upper GI toxicity rate with COX-2 selective inhibitor group. Although some authors suggested that the incidence of upper GI toxicities caused by the use of non-selective NSAID with PPI were higher than the use of selective COX-2 inhibitors [2] , there is no exactly matching study on complication probability of non-selective NSAID with PPI group versus COX-2 selective inhibitor group, thus we made a conservative estimate of the upper GI toxicity rate of NSAID plus PPI group. Second, we assumed that the protective effect of PPI does not influence the incidence and severity of lower GI toxicities and that the development of lower GI toxicity caused by non-selective NSAID with PPI was regarded as same as that caused by non-selective NSAID alone strategy in this study. It has been reported that NSAID is equally associated with upper and lower GI events [17, 18, 20] . The pathogenesis of NSAID-induced enteropathy is initiated by the inhibition of oxidative phosphorylation in the enterocytes exposed to the ingested NSAID and further exacerbated by contact through enterohepatic circulation, and prominent apoptosis combined with increased intraepithelial lymphocyte counts are characteristic features of this condition [27, 28] . Lower GI toxicity of NSAIDs in the small bowel and colon may be independent of acid secretion and the use of anti-secretary agents including PPI does not prevent lower GI complications as compared with the known protective effect for upper GI complications [29] . To eliminate the effect of PPI on lower GI toxicity, we performed sensitivity analysis varying utility estimates, and the recalculated results did not show difference. This indicates that our results are robust to the working assumptions on utility parameters. The price of COX-2 selective inhibitor has been set high, thus it is needed to assess the clinical benefits, costs for adverse events, and cost-effectiveness of COX-2 selective inhibitor compared with non-selective NSAIDs. Most of previous studies focused on pharmacoeconomic analysis regarding upper GI toxicities of NSAID uses. However, recent reports showed that a very high incidence of lower GI damage has been reported in young, healthy, human subjects taking both a non-selective NSAID and a PPI, indicating that the PPI conferred little protection to lower GI tracts, which are major sites of NSAID-induced bleeding and perforation [30] [31] [32] . And several studies showed that COX-2 selective inhibitor could be a better choice to reduce mucosal lesions of the small bowel compared with non-selective NSAID with PPI [33, 34] . Several other economic evaluations of COX-2 selective inhibitor versus NSAID or NSAID plus PPI have been published, all with very different results [35] [36] [37] [38] [39] [40] . In the present study, we analyzed the cost effectiveness of NASID uses associated with the risk of upper and lower GI complications and found that the use of COX-2 selective inhibitor shows reasonable cost effectiveness over non-selective NSAID alone and non-selective NSAID with PPIs. To the best of our knowledge, this is the first study that evaluated cost effectiveness of various NSAIDs use strategies for treatment of RA with regards to both upper and lower GI tract toxicities.
There are several limitations in the present study. We performed a detailed search of the medical literatures, and there were many differences in patient groups, drug regimens, drug doses, and definition of adverse events among the studies, which might influence the rate of GI toxicities. There was no prospective study about GI complications with the same NSAID, thus we extracted most of our data from the CLASS study. There have been difficulties with the interpretation of the CLASS study because of preferential withdrawal of patients with GI risk factors from the NSAID treatment arm. Therefore, a limitation of the present analysis was that the economic perspective, depending on the GI risk of the individual patient was not evaluated. Although it has been suggested that COX-2 selective inhibitor may increase the risk of cardiovascular thromboembolic events via inhibition of vascular prostacyclin synthesis without a corresponding inhibition of platelet thromboxane, no such increase was evident in the CLASS study. This study did not include cardiovascular thrombotic adverse events that NSAID uses can cause [13, 41] . Considering these complications, this study may lead to different conclusion and further studies are expected to consider overall complications including cardiovascular events. In addition, we did not include the indirect cost in this cost-effectiveness analysis. Further work is needed to collect real world evidence including GI toxicity event in Korea as well as indirect cost.
CONCLUSION
The ICER of COX-2 selective inhibitor was superior to those of non-selective NSAID alone and non-selective NSAID with PPI. These data showed that COX-2 selective inhibitor had reasonable cost effectiveness for patients with RA in Korea. There have been no pharmacoeconomic studies comparing cost effectiveness of various NSAIDs strategies with regards to entire GI tract complications. To make a precise comparison about cost effectiveness among COX-2 selective inhibitor, non-selective NSAID alone and non-selective NSAID with PPI, more controlled prospective studies are warranted to compare the therapeutic efficacies, GI complications, and cardiovascular complications.
